





O R G A N

> | S |

N G



Dr. Anil Heroor Director Surgical Oncology, Fortis Hospital, Mumbai




Dr. Tejinder Singh Sr. Consultant Medical Oncologist Apollo Cancer Center, Apollo Hospital, Mumbai



Dr. Adwaita Gore Associate Director Medical Oncology Nanavati Max Super Speciality, Mumbai







Dear Colleagues,

GKCT brings to you the 5th Edition of Annual Review in Gastrointestinal Cancer to be held on 22nd-24th July 2022 on a Virtual Platform.

The primary goal of this meeting is to guide practicing physicians on integrating the best and most current evidence into day-to-day routine care for patients with GI cancers. This meeting brings a practical perspective on how to optimize multidisciplinary care for some of the more complex clinical management decisions. Topics discussed include locoregional modalities, the role of minimally invasive procedures, and state-of-the-art treatment.

As we are aware chemotherapy dependency has maintains its validity in several gastrointestinal cancers and continues to be successfully explored, especially in academic trials. However, a number of biomarkers currently guide treatment decisions for patients with gastrointestinal neoplasms. Major technological advances in genomics have made it possible to identify critical genetic alterations in cancer, rendering oncology well along the path to "personalized cancer medicine".

Image-guided surgery & minimally invasive treatment has evolved over the past several decades, which has led to reduced local recurrence rates and improved survival outcomes. The approach to diagnosis, staging, and selection of appropriate treatment modalities has become a multidisciplinary effort combining interventional endoscopy, surgery, and radiology tools needs to be discussed and implemented in our practice.

This meeting focuses on case-based and didactic presentations from national international experts in the treatment of the whole spectrum of gastrointestinal (GI) cancers, including esophageal, gastric, hepatocellular, pancreatic, small bowel, bile duct, anal and colorectal, and gallbladder. Our year in review session, hall mark surgical video sessions and case based panel discussion will provide an overview of exciting new research in the area of gastrointestinal tumours that may establish the stage for an innovative personalized management and precision medicine modalities for individualized care.

We are sure our attempt in understanding the various therapeutic interventions will pave the way for improved patient outcomes. We look forward to your active participation.

Regards

Dr. Anil Heroor

Director Surgical Oncology, Fortis Hospital, Mumbai

Dr. Adwaita Gore

Associate Director Medical Oncology Nanavati Max Super Speciality, Mumbai







MEETING HIGHLIGHTS

- Surgical Master Video Session
- Year in Review in GI Cancer Session
- Molecular Tumor Board and Case Based Panel Discussion
- Eminent Speaker Sessions (Surgical and Medical)
- Molecular Oncology Session










Day 1 22nd July 2022 Scientific Program **Industry Symposium Sponsored by Bristol Myers Squibb** 6.00pm - 6.30pm Immune checkpoint inhibitors in 1L Gastric Cancer, GEJC and EAC **Speaker: Dr. Tejinder Singh** 6.30pm - 7.00pm **Sponsored by Intas** Role of S1 in GI management in Indian Scenario **Speaker: Dr. Prabhat Bhargava** 7.00pm - 7.30pm Sponsored by AstraZeneca Newer Avenues in Management of **Advanced BTC** Speaker: Dr. B.K. Smruti **Reecent Advances in the** 7.30pm - 8.00pm Management of Second Line **Gastric Cancer** Speaker: Dr. Ashish Singh 8.00pm - 8.30pm **Sponsored by Roche Panel Discussion on Treatment** Strategies with Atezolizumab & **Bevacizumab in Unresectable HCC** Moderator : Dr. Bhushan Nemade Panelists -Dr. Tejinder Singh **Dr. Preetam Jain**

Dr. Aditya Kale Dr Amit Mandot Dr. Rahul Sheth








Day 2 | 23rd July 2022 Scientific Program

Session 1 : Esophagus/Stomach Cancers

	Chairpersons - Dr. Shirish Alurkar Dr. Girish Phadke
6:00pm – 6:10pm	Updates in Surgical Management of Localized EG Cancers Speaker: Dr. M. Satish Kumar
	Speaker. Dr. M. Satish Kumar
6:10pm – 6:20pm	Management of Metastatic EG Cancer
	Speaker: Dr. Pritam Kalaskar
6:20pm – 6:40pm	Should all Patients with EG Cancer Receive Immunotherapy?
	Yes – Dr. M. Vamshi Krishna
	No – Dr. Peush Baipai
	No – Dr. Peush Bajpai
	No – Dr. Peush Bajpai Debate Moderator : Dr. Bharat Bhosale
	Debate Moderator :
6:40pm – 7:10pm	Debate Moderator : Dr. Bharat Bhosale Chairpersons - Dr. Satish Midha
6:40pm – 7:10pm	Debate Moderator : Dr. Bharat Bhosale Chairpersons - Dr. Satish Midha Dr. Atul Sharma Panel Discussion: Practice Changing Papers in Esophageal / Gastric
6:40pm – 7:10pm	Debate Moderator : Dr. Bharat Bhosale Chairpersons - Dr. Satish Midha Dr. Atul Sharma Panel Discussion: Practice Changing Papers in Esophageal / Gastric Cancers

Dr. Rajesh Shinde Dr. Rudraprasad Acharya Dr. Gajanan Kanitkar Dr. Atul Narayankar Dr. Sandeep De Dr. Indranil Mallick Dr. Nikhil Kalyani Dr. Nilesh Lokeshwar Dr. Nikhil Gulavani Dr. Nikhil Gulavani







Day 2 23rd July 2022 Scientific Program

Session 2 : Pancreatic Cancer

	Chairpersons - Dr. D. C. Doval Dr. Abhijit Talukdar
7:10pm – 7:35pm	Debate : Borderline Resectable Pancreatic Cancer
	To Radiate : Dr. Manish Chandra
	Not To Radiate: Dr. Shaikat Gupta
	Debate Moderator: Dr. Adarsh Chaudhary
7:35 – 7:50pm	Advances in the Systemic Treatment of Pancreatic Cancer
	Speaker: Dr. Niti Raizada
	Chairpersons - Dr. Sanjay Sonar Dr. Shefali Agrawal
7:50pm – 8:20pm	Panel Discussion: Practice Changing Papers in Pancreatic Cancers
	Moderator: Dr. Chetan Kantharia
	Panelists: Dr. Rajat Bhargava Dr. Caleb Harris Dr. Ramakrishnan A.S.

Dr. Upasna Saxena Dr. Amol Dongre Dr. Krishnakumar Rathnam Dr. Sujai Hegde







Day 2 23rd July 2022 Scientific Program

Session 3 : Hepatocellular Carcinoma / Ca Gall Bladder

	Chairpersons - Dr. S. H. Advani Dr. Naresh Somani
8:20pm – 8:45pm	Debate : Integrating Immunotherapy Into Earlier-Stage HCC
	Yes – Dr. Pritam Kataria
	Not Yet - Dr. Ravi Jaiswal
	Debate Moderator: Adwaita Gore
8:45pm – 9:00pm	Leaping the Boundaries of Liver Cancer Surgery
	Speaker: Dr. Ganesh Nagrajan
	Chairpersons - Dr. Vivek Agarwala Dr. Shishir Shetty
9:00pm – 9:30pm	Panel Discussion: Practice Changing Papers in HCC/Gall Bladder
	Moderator: Dr. Vineet Talwar
	Panelists: Dr. Shraddha Patkar Dr. Aniruddha Kulkarni Dr. Nikhil Pande Dr. Chandrakanth MV

Dr. Suhas Aagre Dr. Sandeep Bhoriwal Dr. Shailesh Bondarde Dr. Chandrashekhar Pethe







Day 3 24th July 2022 Scientific Program

Session 4 : Colorectal Cancers

	Chairpersons - Dr. K Pavithran Dr. Mehul Bhansali
6:00pm – 6:10pm	Tailoring Treatment for Early-Stage CRC
	Speaker: Dr. Avanish Saklani
6:10pm – 6:35pm	Debate: What's the Best Sequence of Therapy for Locally Advanced Rectal?
	Radiation First : Dr. Reena Engineer Chemotherapy First : Dr. Chetan Deshmukh
6:35pm – 6:45pm	Finding the Optimal Window for Anti-EGFR Treatment Speaker: Dr. Prasad Narayanan
6:45pm – 6:55pm	New and Emerging Later-Line Therapies in Advanced CRC Speaker: Dr. Rahul Kulkarni
6:55pm – 7:20pm	Chairpersons - Dr. Rajeev Joshi Dr. Avinash Supe Debate: Quadruple or Triple Therapy in First-Line Advanced CRC
	Quadruple Therapy : Dr. Bhuvan Chugh

Triplet Therapy Dr. Prabhat Bhargava

Moderator: Dr. Manish Kumar







Day 3 24th July 2022 Scientific Program

Session 4 : Colorectal Cancers

7:20pm – 7:50pm	Panel discussion: Practice Changing Abstracts in CRC
	Moderator: Dr. Nitesh Rohatgi
	Panelists: Dr. Wesley Jose Dr. Nirmal Raut Dr. Smita Kayal Dr. Ashwin Desouza Dr. Deep Goel Dr. Sandeep Nayak Dr. Poornima Subrahmanya
7:50pm – 8:50pm	Chairpersons - Dr. Anuradha Chougule Dr. P. K. Julka Molecular Tumour Board
	Moderator: Dr. T. Raja
	Panelists: Dr. Amit Rauthan Dr. B. K. Smruti Dr. Suparna Rao Dr. Tejinder Singh Dr. Uma Dangi Dr. Bharat Bhosale
8:50pm - 9:00pm	Vote of Thanks


Conference managed by:



Leaders in Streaming Modules

Amey Kadam Conference Secretariat rrcg.amey@gmail.com | Mobile +91 98212 41572







Supported By

Diamond Sponsor




Platinum Sponsors





Gold Sponsors





Silver Sponsors












Reimagining how we heal
















Reference: S-One Trio Package Insert


DPD: Dihydropyrimidine Dehydrogenase











1st Line EGFRm+ metastatic Non Small Cell Lung Cancer



2nd Line locally advanced or metastatic Non Small Cell Lung Cancer Colorectal Cancer



2nd Line advanced or unresectable Hepatocellular Carcinoma

CYRAMZA[™] India prescribing information Dt-6th-May-21, Version 6 *Data on file







1L : 1st Line HCC : Hepatocellular Carcinoma mHCC : metastatic Hepatocellular Carcinoma

1. Finn RS, Qin S, Ikeda M, et al; IMbrave150 Investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.N Engl J Med. 2020;382:1894-1905.



Marketed in India by : Roche Products (India) Pvt. Ltd. 146-B, 166. Unit No. 7,8.9, 8th Floor, R City Office, R City Mall, Lal Bahadur Shastri Marg, Ghatkopar, Mumbai - 400 068, India TeL: +91 (22) 5045 7300 • Fax :+91 (22) 5045 7301






One dose Dual action 5-day prevention¹⁵



PREVENTION MADE SIMPLE





For the management of advanced HCC






- Developed in house right from basic API to finished product*
- Bioequivalent to the innovator
- Manufactured in USFDA approved plant for benchmark quality^{*}



a SUN PHARMA division

* Data on file.





With Best Compliments from



Makers of



RE-SETLife







A / B - 201 / 202, Dipti Classic, 32 / 34. W.T. Suren Road, Andheri (East), Mumbai - 400 093, India Tel: +91 22 2684 93 38 / 39 / 40 Fax: +91 22 2684 9355 E-mail: ho@heterohealthcare.com